The Safety And Efficacy Of Enoxaparin In PCI For Patients With Non-ST Segment Elevated Myocardial Infarction

Objective To evaluate the efficacy and safety of using enoxaparin with no adding UFH in the patients with non-ST elevated myocardial infarction (NSTEMI) underwent percutaneous coronary intervention(PCI).Methods From April to Octorber in 2007, 109 patients with NSTEMI underwent PCI via femoral artery were randomized into 2 groups : the low molecule weight heparin group (LMWH) which receive enoxaparin (1mg/kg q12h subcutaneously, at least within 48h before CAG/PCI and the sheath was withdrawn immediately after the operation, n=55 )and UFH group (enoxaparin 1mg/kg q12h subcutaneously, at least within 48h, add to 100u/kg during CAG/PCI and the sheath was withdrawn 4h after the operation, n=54 ).The cardiac MACE including death, re-AMI,TLR, thrombosis events were observed and compared between the 2 groups.Results 1. No death, re-AMI, TLR, thrombosis events occurred in both LMWH group and UFH group during hospitalization and 1 month follow- up;2. Femoral Hematoma at the puncture site was 1.85 % vs 12.73 % ( P <0.05) in LMWH and UFH group respectively.3. The incidence of upper gastrointestinal bleeding events were 0 in the LMWH group and 1.8% in the UFH group (P=0.32).Conclusion It is safe and efficient for NSTEMI patients not adding heparin during CAG/PCI if enoxaparin 1mg/kg q12h was given subcutaneously at least within 48 hrs. It is also safe to withdraw the sheathe immediately after PCI.